WEC
LOGC

Winslow Evans & Crocker’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Winslow Evans & Crocker’s Portfolio LOGC Stock Details LOGC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$1K Buy
+176
New +$1.18K ﹤0.01% 1302

Other funds holding LOGC

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
SC
Samlyn Capital New York $5.86B AUM 36.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Winslow Evans & Crocker's LOGC Position: Q4 2020 in Review

Winslow Evans & Crocker opened a new position in LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q4 2020: 176 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #1302 among its holdings.

59 funds tracked by Wall St. Rank hold LOGC as of Q4 2020.

  • Winslow Evans & Crocker held 176 shares of LogicBio Therapeutics, Inc. Common Stock worth $1K as of Q4 2020.
  • LogicBio Therapeutics, Inc. Common Stock was a new Winslow Evans & Crocker position in Q4 2020.
  • LogicBio Therapeutics, Inc. Common Stock made up ﹤0.01% of Winslow Evans & Crocker's portfolio in Q4 2020, its #1302 holding.
  • 59 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q4 2020.

Based on Winslow Evans & Crocker's 13F filing for Q4 2020, filed 3 Feb 2021.